KRAS and colorectal cancer: Oncogenic KRAS was shown to inhibit the expression of STAT1, STAT2 and IRF9 (members of the ISGF3 transcription-promoting complex); thus, hampering the basal and IFN-induced expression of ISGs in colorectal cancer cell lines [22].